DarioHealth Corp. (DRIO)
USD 0.65
(-9.08%)
USD 0.65
(-9.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -53.49 Million USD | 2.97% |
| 2022 | -56.81 Million USD | 28.21% |
| 2021 | -73.11 Million USD | -141.99% |
| 2020 | -29.71 Million USD | -72.32% |
| 2019 | -17.52 Million USD | -0.68% |
| 2018 | -17.48 Million USD | -33.0% |
| 2017 | -14.22 Million USD | -25.56% |
| 2016 | -10.44 Million USD | -31.09% |
| 2015 | -7.36 Million USD | 33.78% |
| 2014 | -10.32 Million USD | 3.52% |
| 2013 | -13.09 Million USD | -430.34% |
| 2012 | -2.34 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -14.23 Million USD | 13.16% |
| 2024 Q1 | -15.78 Million USD | -34.02% |
| 2023 FY | - USD | 2.97% |
| 2023 Q3 | -15.54 Million USD | -21.44% |
| 2023 Q2 | -12.8 Million USD | -17.31% |
| 2023 Q4 | -12.75 Million USD | 17.95% |
| 2023 Q1 | -10.91 Million USD | -45.38% |
| 2022 Q4 | -7.5 Million USD | 43.76% |
| 2022 Q3 | -13.34 Million USD | 17.34% |
| 2022 Q2 | -16.14 Million USD | -8.98% |
| 2022 Q1 | -14.81 Million USD | 29.69% |
| 2022 FY | - USD | 28.21% |
| 2021 FY | - USD | -141.99% |
| 2021 Q1 | -13.28 Million USD | -47.36% |
| 2021 Q2 | -17.2 Million USD | -29.51% |
| 2021 Q3 | -21.14 Million USD | -22.89% |
| 2021 Q4 | -21.07 Million USD | 0.32% |
| 2020 FY | - USD | -72.32% |
| 2020 Q1 | -10.29 Million USD | -146.14% |
| 2020 Q2 | -4.07 Million USD | 60.38% |
| 2020 Q4 | -9.01 Million USD | -37.53% |
| 2020 Q3 | -6.55 Million USD | -60.76% |
| 2019 Q2 | -5.18 Million USD | 2.35% |
| 2019 Q4 | -4.18 Million USD | -53.49% |
| 2019 FY | - USD | -0.68% |
| 2019 Q1 | -5.31 Million USD | -4.96% |
| 2019 Q3 | -2.72 Million USD | 47.46% |
| 2018 Q4 | -5.05 Million USD | -30.66% |
| 2018 Q2 | -5.67 Million USD | -101.38% |
| 2018 Q1 | -2.82 Million USD | -150.68% |
| 2018 FY | - USD | -33.0% |
| 2018 Q3 | -3.87 Million USD | 31.82% |
| 2017 FY | - USD | -25.56% |
| 2017 Q4 | 5.56 Million USD | 289.83% |
| 2017 Q3 | -2.93 Million USD | 28.25% |
| 2017 Q2 | -4.08 Million USD | 64.83% |
| 2017 Q1 | -11.61 Million USD | -949.14% |
| 2016 FY | - USD | -31.09% |
| 2016 Q1 | -2.55 Million USD | -29.9% |
| 2016 Q2 | -2.44 Million USD | 4.49% |
| 2016 Q3 | -4.29 Million USD | -75.82% |
| 2016 Q4 | -1.1 Million USD | 74.24% |
| 2015 Q4 | -1.97 Million USD | 38.72% |
| 2015 Q2 | -902 Thousand USD | 51.0% |
| 2015 Q1 | -1.84 Million USD | -239.67% |
| 2015 FY | - USD | 33.78% |
| 2015 Q3 | -3.21 Million USD | -256.43% |
| 2014 Q3 | -5 Million USD | -30.59% |
| 2014 Q4 | -542 Thousand USD | 89.18% |
| 2014 Q2 | -3.83 Million USD | -47.1% |
| 2014 Q1 | -2.6 Million USD | 63.22% |
| 2014 FY | - USD | 3.52% |
| 2013 Q1 | -822.9 Thousand USD | 58.29% |
| 2013 Q2 | -1.73 Million USD | -110.92% |
| 2013 Q4 | -7.08 Million USD | -190.01% |
| 2013 Q3 | -2.44 Million USD | -40.82% |
| 2013 FY | - USD | -430.34% |
| 2012 Q2 | -869.49 Thousand USD | -69.04% |
| 2012 Q4 | -1.97 Million USD | -294.75% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | -514.36 Thousand USD | 0.0% |
| 2012 Q3 | 1.01 Million USD | 216.51% |
| 2001 Q2 | -18 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 74.956% |
| Prenetics Global Limited | -47.89 Million USD | -11.688% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -3070.954% |
| CareDx, Inc | -89.65 Million USD | 40.335% |
| Exact Sciences Corporation | 41.87 Million USD | 227.744% |
| Exagen Inc. | -19.15 Million USD | -179.298% |
| Inotiv, Inc. | -26.5 Million USD | -101.818% |
| Guardant Health, Inc. | -433.3 Million USD | 87.654% |
| Biodesix, Inc. | -37.1 Million USD | -44.177% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -2052.537% |
| Precipio, Inc. | -4.31 Million USD | -1138.861% |
| iSpecimen Inc. | -9.1 Million USD | -487.606% |
| Natera, Inc. | -383.27 Million USD | 86.043% |
| Aspira Women's Health Inc. | -16.49 Million USD | -224.383% |
| Standard BioTools Inc. | -54.45 Million USD | 1.768% |
| 23andMe Holding Co. | -291.87 Million USD | 81.672% |
| Castle Biosciences, Inc. | -45.02 Million USD | -18.812% |
| Personalis, Inc. | -96.8 Million USD | 44.742% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 54.498% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -457.75% |
| OpGen, Inc. | -29.51 Million USD | -81.268% |
| T2 Biosystems, Inc. | -43.87 Million USD | -21.924% |
| Myriad Genetics, Inc. | -67.8 Million USD | 21.1% |
| ICON Public Limited Company | 1.63 Billion USD | 103.278% |
| NeoGenomics, Inc. | -17.6 Million USD | -203.822% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -3070.954% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 104.393% |
| RadNet, Inc. | 292.78 Million USD | 118.271% |
| MDxHealth SA | -30.46 Million USD | -75.574% |
| Psychemedics Corporation | -251 Thousand USD | -21212.351% |
| Illumina, Inc. | -608 Million USD | 91.202% |
| Check-Cap Ltd. | -17.64 Million USD | -203.099% |
| Twist Bioscience Corporation | -176.7 Million USD | 69.727% |
| Fulgent Genetics, Inc. | -46.55 Million USD | -14.912% |
| Sera Prognostics, Inc. | -35.28 Million USD | -51.597% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -446.705% |
| OPKO Health, Inc. | -65.51 Million USD | 18.35% |
| Medpace Holdings, Inc. | 363.15 Million USD | 114.73% |
| Neogen Corporation | 182.59 Million USD | 129.296% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -507.148% |
| Prenetics Global Limited | -47.89 Million USD | -11.688% |
| Mainz Biomed B.V. | -25.01 Million USD | -113.88% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -601.165% |
| Trinity Biotech plc | -24.09 Million USD | -121.985% |
| Neuronetics, Inc. | -22.75 Million USD | -135.045% |
| Sotera Health Company | 514.14 Million USD | 110.405% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -601.165% |